RBC Capital Reiterates Hookipa Pharma (HOOK) Outperform Recommendation
Fintel reports that on June 30, 2023, RBC Capital reiterated coverage of Hookipa Pharma (NASDAQ:HOOK) with a Outperform recommendation.
Analyst Price Forecast Suggests 468.05% Upside
As of June 2, 2023, the average one-year price target for Hookipa Pharma is 4.53. The forecasts range from a low of 0.50 to a high of $8.40. The average price target represents an increase of 468.05% from its latest reported closing price of 0.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Hookipa Pharma is 18MM, an increase of 10.76%. The projected annual non-GAAP EPS is -0.98.
What is the Fund Sentiment?
There are 71 funds or institutions reporting positions in Hookipa Pharma. This is a decrease of 11 owner(s) or 13.41% in the last quarter. Average portfolio weight of all funds dedicated to HOOK is 0.01%, an increase of 34.72%. Total shares owned by institutions decreased in the last three months by 6.46% to 23,580K shares. 
The put/call ratio of HOOK is 0.09, indicating a bullish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 3,476K shares representing 6.35% ownership of the company. No change in the last quarter.
Redmile Group holds 2,553K shares representing 4.67% ownership of the company. In it's prior filing, the firm reported owning 3,115K shares, representing a decrease of 22.01%. The firm decreased its portfolio allocation in HOOK by 21.00% over the last quarter.
EcoR1 Capital holds 2,473K shares representing 4.52% ownership of the company. No change in the last quarter.
Artal Group holds 1,850K shares representing 3.38% ownership of the company. No change in the last quarter.
FBIOX - Biotechnology Portfolio holds 1,480K shares representing 2.70% ownership of the company. No change in the last quarter.
Hookipa Pharma Background Information
(This description is provided by the company.)
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.
Key filings for this company:
This story originally appeared on Fintel.